| Literature DB >> 27983697 |
Patrizia Ambrogini1, Michele Betti2, Claudia Galati3, Michael Di Palma4, Davide Lattanzi5, David Savelli6, Francesco Galli7, Riccardo Cuppini8, Andrea Minelli9.
Abstract
Neuroplasticity is an "umbrella term" referring to the complex, multifaceted physiological processes that mediate the ongoing structural and functional modifications occurring, at various time- and size-scales, in the ever-changing immature and adult brain, and that represent the basis for fundamental neurocognitive behavioral functions; in addition, maladaptive neuroplasticity plays a role in the pathophysiology of neuropsychiatric dysfunctions. Experiential cues and several endogenous and exogenous factors can regulate neuroplasticity; among these, vitamin E, and in particular α-tocopherol (α-T), the isoform with highest bioactivity, exerts potent effects on many plasticity-related events in both the physiological and pathological brain. In this review, the role of vitamin E/α-T in regulating diverse aspects of neuroplasticity is analyzed and discussed, focusing on the hippocampus, a brain structure that remains highly plastic throughout the lifespan and is involved in cognitive functions. Vitamin E-mediated influences on hippocampal synaptic plasticity and related cognitive behavior, on post-natal development and adult hippocampal neurogenesis, as well as on cellular and molecular disruptions in kainate-induced temporal seizures are described. Besides underscoring the relevance of its antioxidant properties, non-antioxidant functions of vitamin E/α-T, mainly involving regulation of cell signaling molecules and their target proteins, have been highlighted to help interpret the possible mechanisms underlying the effects on neuroplasticity.Entities:
Keywords: adult neurogenesis; brain; development; neuroplasticity; seizures; vitamin E
Mesh:
Substances:
Year: 2016 PMID: 27983697 PMCID: PMC5187907 DOI: 10.3390/ijms17122107
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Phosphorylation of protein kinase C (PKC) and PKC substrates are reduced in developing hippocampus of α-tocopherol-exposed pups. (A) PKCpan, PKCα and PKCδ phosphorylation in the hippocampus of developing offspring and PKCpan phosphorylation in the hippocampus of adult offspring; (B) Phosphorylation of PKC substrates GAP-43 and MARCKS in the hippocampus of developing and adult offspring. Hippocampal protein extracts taken from CTRL and TREAT developing and adult offspring (at each time point, for each group, n = 8 animals from four different litters) were subjected to SDS/PAGE (12% polyacrylamide for PKCpan, PKCα, PKCδ and GAP-43 and 7% polyacrylamide for MARCKS) followed by Western blotting, using polyclonal phospho-specific antibody directed to PKCpan, PKCα, PKCδ, GAP-43 and MARKS. Histograms represent densitometric analyses of blots from three independent experiments (means ± S.E.M.). Representative CTRL value is shown as dashed line. Relative decreases in band absorbance values (arbitrary units) were normalized for the control band in each series. Student’s t test: * p < 0.05. Figure modified from [78]. GAP: growth associated protein; MARCKS: myristoylated alanine-rich C-kinase substrate; CTRL: control, untreated; TREAT: treated.
Figure 2α-Tocopherol treatment decreases hippocampal neuroinflammation in kainate-induced status epilepticus. (A) GFAP (glial fibrillary acidic protein) immunoreactivity expressed as percent of area fluorescence; (B) GS (glutamine synthetase) immunoreactivity expressed as percent of area fluorescence; (C) Branch point number of Iba1 (ionized calcium-binding adapter molecule 1)-positive microglial cells; (D) Process length of Iba1-positive microglial cells; (E) Western blotting analysis of neuroinflammatory markers GFAP, MHC II, IL-1β and TNF-α in hippocampus protein extracts obtained from CTRL and TREAT rats. Representative non-epileptic and untreated animals’ value is shown as dashed line. Statistical analyses performed by one-way ANOVA and Tukey’s post hoc test: * p < 0.05; ** p < 0.01. CTRL: kainate-exposed untreated rats. TREAT: kainate-exposed α-tocopherol treated rats. Figure modified from [276]. MHC II: major histocompatibility complex II; IL-1β, interleukin 1 β; TNF-α: tumor necrosis factor α.
Figure 3Effect of α-tocopherol treatment on hippocampal neurodegeneration induced by status epilepticus. (A) Degenerating neurons quantified as FluorJade-positive cells along rostro-caudal extension of CA1 field; (B) Neurofilament immunoreactivity expressed as percent of area fluorescence; (C) Dendritic spine number quantified per unit length of dendrite; (D) Synaptophysin immunoreactivity expressed as percent of area fluorescence. Statistical analyses performed by (A) Student’s t test: ** p < 0.01 and (B–D) one-way ANOVA and Tukey’s post hoc test: * p < 0.05; ** p < 0.01. Figure modified from [276].
Figure 4α-Tocopherol treatment per se affects neuroinflammation in non-epileptic rats. (A) TNF-α western blotting quantification in hippocampus protein extracts of CTRL and TREAT rats: TNF-α was significantly reduced following α-tocopherol treatment in the absence of seizures; (B) Process length of Iba1-positive microglial cells: The graph shows a significantly longer microglial processes, indicating the influence of α-tocopherol in determining microglia morphology and activity in normal rats. Statistical analyses performed by one-way ANOVA and Tukey’s post hoc test: ** p < 0.01. TREAT: non epileptic α-tocopherol-treated rats. CTRL: non epileptic rats’ untreated rats. Figure modified from [276].